Mylan claims good Samaritan cause in FDA case over generic Lipitor
This article was originally published in Scrip
Executive Summary
Mylan claims that its efforts to push the US FDA to decide on and make public its position on the status of Ranbaxy's ANDA for generic Lipitor (atorvastatin) and the Indian firm's potential six-month exclusivity period for its version of the Pfizer product are all in the larger good of industry.